Canine synovial sarcoma: a retrospective assessment of described prognostic criteria in 16 cases (1994-1999).
Pertinent patient data and biopsied tissue from 16 cases of canine synovial sarcoma (SS) were reviewed. Histopathological grade, clinical stage, and tissue immunoreactivity to cytokeratin (broad stain, AE1/AE3 and cytokeratin 7) and vimentin were determined and correlated with survival. Effect of treatment on survival was similarly evaluated. Neither clinical stage nor histopathological grade significantly affected survival patterns. Tissues from all cases stained >30% positively with vimentin, whereas no tissue from any case exhibited cytokeratin immunoreactivity. Dogs receiving surgical tumor excision or amputation had a significantly higher survivability than those receiving no treatment (P<0.02). Treatment aggressiveness may be more appropriate than clinical staging or tumor grading in predicting survival. Reliability of diagnosing and prognosticating canine SS with current immunohistochemistry protocols should be questioned.
Fox
Derek B
DB
Comparative Orthopaedic Laboratory, College of Veterinary Medicine, University of Missouri-Columbia, 65211, USA.
Cook
James L
JL
Kreeger
John M
JM
Beissenherz
Marilyn
M
Henry
Carolyn J
CJ
D000671:Amputation, Surgical / Q000662:veterinary; D000818:Animals; D004283:Dog Diseases / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D004285:Dogs; D005260:Female; D007150:Immunohistochemistry / Q000662:veterinary; D007633:Keratins; D008297:Male; D008923:Missouri / Q000453:epidemiology; D009367:Neoplasm Staging / Q000662:veterinary; D011379:Prognosis; D011996:Records / Q000662:veterinary; D012189:Retrospective Studies; D013584:Sarcoma, Synovial / Q000401:mortality / Q000662:veterinary*; D016019:Survival Analysis; D014746:Vimentin
D014746:Vimentin; D007633:Keratins